Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice

Biochem Biophys Res Commun. 2010 Mar 19;393(4):829-35. doi: 10.1016/j.bbrc.2010.02.092. Epub 2010 Feb 18.


CD27 plays an important role in T-cell co-stimulation and is also expressed on lymphomas. In the present study, we generated novel depleting and non-depleting monoclonal antibodies (mAbs) against mouse CD27 and characterized their co-stimulatory activity in vitro and anti-tumor effects in immune-competent mice bearing syngeneic T-cell lymphoma (EG7) expressing or lacking CD27. A profound anti-tumor effect was observed with a non-depleting mAb (RM27-3E5), but not with a depleting mAb (RM27-3C1), against either EG7/CD27(+) or EG7/CD27(-) tumors, which was associated with the induction of EG7-specific cytotoxic T lymphocytes (CTLs). Consistently, the anti-tumor effect of RM27-3E5 was abolished in T cell-deficient nude mice. These results indicate that a non-depleting agonistic mAb against CD27 is promising for cancer therapy by co-stimulating tumor-specific CTL induction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Lymphocyte Activation*
  • Lymphocyte Depletion
  • Lymphoma, T-Cell / immunology
  • Lymphoma, T-Cell / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / antagonists & inhibitors*
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / immunology


  • Antibodies, Monoclonal
  • Tumor Necrosis Factor Receptor Superfamily, Member 7